Hepbest Tablets

Q1: What is Hepbest (Tenofovir Alafenamide 25mg) used for?

Hepbest contains Tenofovir Alafenamide (TAF) 25mg, approved for both HIV-1 treatment (as part of combination therapy) and chronic hepatitis B treatment. It is the modern replacement for Tenofovir Disoproxil Fumarate (TDF) with better safety for kidneys and bones.

Q2: How does TAF achieve lower toxicity than TDF?

TAF is a pro-drug that is activated preferentially inside target cells (lymphocytes, hepatocytes), requiring 90% lower systemic plasma concentrations than TDF to achieve equivalent intracellular antiviral activity. The dramatically lower systemic exposure explains the substantially reduced kidney and bone toxicity.

Q3: How is Hepbest 25mg taken?

Take 25mg once daily WITH food — food significantly enhances TAF absorption and should not be omitted. Take consistently at the same time each day for optimal drug levels.

Q4: Why is Hepbest important for hepatitis B treatment?

Tenofovir (both TDF and TAF) has a high barrier to HBV resistance, making it preferred for long-term HBV suppression. TAF achieves similar HBV suppression to TDF at much lower kidney and bone cost — important for the lifelong treatment required in chronic HBV.

Q5: Can Hepbest be stopped without consequences?

No. In HBV-infected patients (including HIV/HBV co-infected), stopping TAF without alternative HBV coverage can cause severe acute hepatitis flare (ALT spike, liver failure risk). This is particularly dangerous in patients with cirrhosis. Never stop without specialist guidance.

Q6: What are the most common side effects?

Hepbest is generally well-tolerated. Common side effects include nausea, diarrhea, headache, fatigue, and weight changes. Weight gain has been associated with TAF-based regimens compared to TDF.

Q7: Is Hepbest safe for patients with kidney disease?

Yes. TAF can be used in patients with eGFR as low as 15 ml/min (dialysis patients for HBV treatment), compared to TDF's minimum eGFR of 30 ml/min. Regular kidney function monitoring is still recommended, though at less frequent intervals.

Q8: Does TAF affect bone density?

TAF causes significantly less bone mineral density reduction than TDF (1–2% loss vs 2–3% loss). This makes Hepbest preferable for patients with osteoporosis, osteopenia, or fracture risk.

Q9: What drug interactions affect Hepbest?

P-gp inducers (rifampicin, carbamazepine) reduce TAF levels — separate dosing consideration needed. P-gp and breast cancer resistance protein inhibitors increase TAF levels — 10mg TAF is used in some fixed-dose combinations with cobicistat/ritonavir boosting.

Q10: Can Hepbest be used during pregnancy?

TAF has limited but growing pregnancy data. TDF has more established pregnancy safety data. For HBV mono-infection: TDF is typically preferred in pregnancy. For HIV treatment: discuss with HIV and obstetric specialists.

Q11: How should Hepbest be stored?

Store at room temperature away from moisture and light. Keep in original packaging out of reach of children. Do not use after the expiry date.

Q12: Do I need a prescription for Hepbest?

Yes. Hepbest requires specialist prescribing (hepatologist or HIV specialist) with baseline HBV/HIV assessment and regular liver function, renal function, and viral load monitoring.